Ra Capital Management, L.P. - Insider Trading & Ownership

Entity
Company
Location
200 Berkeley Street, 18 Th Floor, Boston, Massachusetts
Summary
The estimated value of insider holdings of Ra Capital Management, L.P. is at least $1.61 B dollars as of July 1, 2024. Ra Capital Management, L.P. is the Director, 10%+ Owner of Aerovate Therapeutics, Inc. and owns shares of Aerovate Therapeutics, Inc. (AVTE) stock worth about $198 M. Ra Capital Management, L.P. is the Former 10% Owner of iTeos Therapeutics, Inc. and owns shares of iTeos Therapeutics, Inc. (ITOS) stock worth about $137 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Nkarta, Inc. and owns shares of Nkarta, Inc. (NKTX) stock worth about $131 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Tyra Biosciences, Inc. and owns shares of Tyra Biosciences, Inc. (TYRA) stock worth about $130 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Cytek Biosciences, Inc. and owns shares of Cytek Biosciences, Inc. (CTKB) stock worth about $127 M. Ra Capital Management, L.P. is the 10%+ Owner of AN2 Therapeutics, Inc. and owns shares of AN2 Therapeutics, Inc. (ANTX) stock worth about $98.2 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of PepGen Inc. and owns shares of PepGen Inc. (PEPG) stock worth about $97.7 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of ARS Pharmaceuticals, Inc. and owns shares of ARS Pharmaceuticals, Inc. (SPRY) stock worth about $97.5 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Wave Life Sciences Ltd. and owns shares of Wave Life Sciences Ltd. (WVE) stock worth about $91 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of 89bio, Inc. and owns shares of 89bio, Inc. (ETNB) stock worth about $83.7 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Acrivon Therapeutics, Inc. and owns shares of Acrivon Therapeutics, Inc. (ACRV) stock worth about $67.3 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Janux Therapeutics, Inc. and owns shares of Janux Therapeutics, Inc. (JANX) stock worth about $65.1 M. Ra Capital Management, L.P. is the Director of Mineralys Therapeutics, Inc. and owns shares of Mineralys Therapeutics, Inc. (MLYS) stock worth about $47.7 M. Ra Capital Management, L.P. is the 10%+ Owner of Kala Pharmaceuticals, Inc. and owns shares of KALA BIO, Inc. (KALA) stock worth about $47.4 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Acumen Pharmaceuticals, Inc. and owns shares of Acumen Pharmaceuticals, Inc. (ABOS) stock worth about $45.3 M. Ra Capital Management, L.P. is the 10%+ Owner of Fulcrum Therapeutics, Inc. and owns shares of Fulcrum Therapeutics, Inc. (FULC) stock worth about $38.4 M. Ra Capital Management, L.P. is the Former 10% owner of Enliven Therapeutics, Inc. and owns shares of Enliven Therapeutics, Inc. (ELVN) stock worth about $32.1 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Solid Biosciences Inc. and owns shares of Solid Biosciences Inc. (SLDB) stock worth about $23.2 M. Ra Capital Management, L.P. is the Director of Therapeutics Acquisition Corp. and owns shares of POINT Biopharma Global Inc. (PNT) stock worth about $13.7 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of LENZ Therapeutics, Inc. and owns shares of LENZ Therapeutics, Inc. (GRPH) stock worth about $13.5 M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Eliem Therapeutics, Inc. and owns shares of Eliem Therapeutics, Inc. (ELYM) stock worth about $11 M. Ra Capital Management, L.P. is the 10%+ Owner of RxSight, Inc. and owns shares of RxSight, Inc. (RXST) stock worth about $10.3 M. Ra Capital Management, L.P. is the Director of Black Diamond Therapeutics, Inc. and owns shares of Black Diamond Therapeutics, Inc. (BDTX) stock worth about $8.77 M.
All Insider Reports
All Insider Reports

Ownership of Ra Capital Management, L.P.

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
AVTE Aerovate Therapeutics, Inc. Director, 10%+ Owner $198 M Jun 17, 2024
ITOS iTeos Therapeutics, Inc. Former 10% Owner $137 M +$100 M +270% May 10, 2024
NKTX Nkarta, Inc. Director, 10%+ Owner $131 M +$60 M +85.1% Jun 13, 2024
TYRA Tyra Biosciences, Inc. Director, 10%+ Owner $130 M May 29, 2024
CTKB Cytek Biosciences, Inc. Director, 10%+ Owner $127 M Mar 14, 2022
ANTX AN2 Therapeutics, Inc. 10%+ Owner $98.2 M +$16 M +19.5% Aug 18, 2023
PEPG PepGen Inc. Director, 10%+ Owner $97.7 M +$27.2 M +38.6% Jun 20, 2024
SPRY ARS Pharmaceuticals, Inc. Director, 10%+ Owner $97.5 M +$44.7 M +84.8% Jun 20, 2024
WVE Wave Life Sciences Ltd. Director, 10%+ Owner $91 M +$10 M +12.3% Dec 11, 2023
ETNB 89bio, Inc. Director, 10%+ Owner $83.7 M +$30.7 M +58% Mar 4, 2024
ACRV Acrivon Therapeutics, Inc. Director, 10%+ Owner $67.3 M Jun 20, 2024
JANX Janux Therapeutics, Inc. Director, 10%+ Owner $65.1 M +$77.4 M Jun 26, 2024
MLYS Mineralys Therapeutics, Inc. Director $47.7 M May 22, 2024
KALA KALA BIO, Inc. 10%+ Owner $47.4 M May 26, 2022
ABOS Acumen Pharmaceuticals, Inc. Director, 10%+ Owner $45.3 M +$40 M +759% Jun 10, 2024
FULC Fulcrum Therapeutics, Inc. 10%+ Owner $38.4 M Jan 20, 2023
ELVN Enliven Therapeutics, Inc. Former 10% owner $32.1 M Feb 23, 2023
SLDB Solid Biosciences Inc. Director, 10%+ Owner $23.2 M +$5 M +27.5% Jan 11, 2024
PNT POINT Biopharma Global Inc. Director $13.7 M Jun 29, 2021
GRPH LENZ Therapeutics, Inc. Director, 10%+ Owner $13.5 M Mar 21, 2024
ELYM Eliem Therapeutics, Inc. Director, 10%+ Owner $11 M +$50 M Jun 27, 2024
RXST RxSight, Inc. 10%+ Owner $10.3 M Aug 3, 2021
BDTX Black Diamond Therapeutics, Inc. Director $8.77 M Jul 5, 2023
ICVX Icosavax, Inc. Director, 10%+ Owner $0 Feb 19, 2024
BOLD Boundless Bio, Inc. 10%+ Owner Apr 2, 2024
CDTX Cidara Therapeutics, Inc. Director Apr 26, 2024
DICE DICE Therapeutics, Inc. Former 10% owners and Director Aug 9, 2023
FMTX Forma Therapeutics Holdings, Inc. Director, 10%+ Owner Oct 14, 2022
STSA Satsuma Pharmaceuticals, Inc. Former 10% Owner Jun 8, 2023
VOR Vor Biopharma Inc. Director, 10%+ Owner May 23, 2024
HOWL Werewolf Therapeutics, Inc. Director, 10%+ Owner May 24, 2024

Insider Transactions Reported by Ra Capital Management, L.P.:

Sym Company Class Transaction % Value $ Price $ Shares Shares After Date Ownership